The Lupiae Study
Research type
Research Study
Full title
The Lupiae Study - Towards personalized medicine for refractory/relapsed Follicular Lymphoma patients: the Cantera/Lupiae registry
IRAS ID
285142
Contact name
Kim Linton
Contact email
Sponsor organisation
EHA Lymphoma Group (EHA-LyG)
Duration of Study in the UK
7 years, 0 months, 1 days
Research summary
Follicular lymphoma (FL) is the second most frequent non-Hodgkin lymphoma in western countries and the incidence is rising. The clinical course of FL is typically indolent which means progression is slow and the disease is often diagnosed at an advanced stage. FL patients typically respond well to initial treatment however this is not a curable disease and most patients experience a chronic relapsing course with shortening periods of remission and increased risks of drug resistance. Most patients eventually stop responding to current standard treatments and eventually die of their disease.
Around 20% of newly diagnosed FL patients will undergo early progression which is defined as progression within 24 months of initiation of first systemic treatment. The optimal treatment strategy for patients with a short initial remission is not well defined and current knowledge is insufficient to guide treatment decisions in high risk patients. Treatment choice may be guided by factors such as stage of disease, patient age, general well-being and treatment purpose, as well as patient choice. New agents in development are offering more options to patients but increased knowledge of the biology of FL and effectiveness of these agents is required.
This is a prospective observational study collecting clinical and biological information from FL patients aimed at improving FL characterisation. New knowledge will determine whether disease characteristics are linked to outcomes of treatment and whether this could be used to determine the best treatment strategy at relapse.
REC name
London - Bromley Research Ethics Committee
REC reference
23/PR/0464
Date of REC Opinion
10 Aug 2023
REC opinion
Further Information Favourable Opinion